biostudies-literatureMonk BJNCI NIH HHS981-992https://www.ebi.ac.uk/biostudies/studies/S-EPMC11934258biostudies-literatureUnknown35(11)<h4>Background</h4>The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.<h4>Patients and methods</h4>Patients were randomized 2:1 to niraparib or placebo, stratified by response to first-line treatment, receipt of neoadjuvant chemotherapy, and tumor HRD status. After reaching 60% target maturity, OS was evaluated via a stratified log-rank test using randomization stratification factors and summarized using Kaplan-Meier methodology. OS testing was hierarchicAnnals of oncology : official journal of the European Society for Medical OncologyNiraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.PMC11934258P30 CA008748Heitz FVulsteke CPerez MJRGaba LBruchim IBarretina-Ginesta MPO'Malley DMMoore RGMirza MRBradley WHPisano CMonk BJShtessel LRedondo AHaslund CAChase DMMalinowska IALorusso DHolman LLVergote IDiSilvestro PO'Cearbhaill REPothuri BMcCormick CCHerzog TJGraybill WGonzalez-Martin ACompton NShahin MSFreyer GfalseNiraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.<h4>Background</h4>The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.<h4>Patients and methods</h4>Patients were randomized 2:1 to niraparib or placebo, stratified by response to first-line treatment, receipt of neoadjuvant chemotherapy, and tumor HRD status. After reaching 60% target maturity, OS was evaluated via a stratified log-rank test using randomization stratification factors and summarized using Kaplan-Meier methodology. OS testing was hierarchic2024-01-01T00:00:00Z2024 Nov2026-06-05T09:24:16.664Z2026-05-15T03:13:01.386ZS-EPMC119342583928438110.1016/j.annonc.2024.08.2241